Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis

PHASE2TerminatedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Multiple Sclerosis, Relapsing-RemittingClinically Isolated Syndrome
Interventions
BIOLOGICAL

Tovaxin

2 mL subcutaneous injections administered by a healthcare provider at weeks 0, 4, 8, 12, and 24 every year as required.

Trial Locations (27)

11501

Winthrop University Hospital - Clinical Trials Unit, Mineola

12205

Upstate Clinical Research, LLC, Albany

19104

University of Pennsylvania, Philadelphia

27607

Raleigh Neurology Associates, Raleigh

28204

Neurology Consultants of the Carolinas, PA, Charlotte

30912

Medical College of Georgia - Department of Neurology, Augusta

33060

Neurological Associates, Pompano Beach

34205

Bradenton Neurology, Bradenton

35058

North Central Neurology Associates, PC, Cullman

40503

Associates in Neurology, Lexington

43221

Neurological Research Institute, Columbus

44302

Neurology & Neuroscience Associates, Inc., Akron

45408

Neurology Specialists, Inc, Dayton

46805

Allied Physicians Inc, Fort Wayne

48604

St Mary's of Michigan - Field Neuroscience Institute, Saginaw

60062

Consultants in Neurology, Ltd., Northbrook

66214

MidAmerica Neuroscience Institute, Lenexa

77030

The Maxine Mesinger MS Clinic/Baylor College of Medicine, Houston

78229

Integra Clinical Research, LLC, San Antonio

78681

Central Texas Neurology, Round Rock

80919

Patricia A Fodor, PC, Colorado Springs

85013

Xenoscience - 21st Century Neurology, Phoenix

85050

HOPE Research Institute, Phoenix

94705

Alta Bates Summit Medical Center - East Bay Physicians Medical Group, Berkeley

97225

Providence St. Vincent Medical Center - Northwest MS Center, Portland

98101

MS Center at Evergreen, Kirkland

03766

Ayres & Associates Clinical Trials, Lebanon

Sponsors
All Listed Sponsors
lead

Opexa Therapeutics, Inc.

INDUSTRY